Malignant lymphomas, Solid tumors Malignant lymphoma
Conditions
Interventions
none
Sponsors
Shimoyama Tatsu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subject must satisfy the inclusion criteria (4.3.2) among the subjected patients (4.3.1) and do not meet any of the exclusion criteria. 4.3.1 Subjected patient Patients with malignant lymphoma or solid cancer* treated in Tokyo Metropolitan Komagome Hospital (* stomach cancer, colon cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, head and neck cancer, etc.) 4.3.2 Inclusion criteria Subject is 20 years or older of age at the time of obtaining consent. Histologically or cytologically proven malignant tumor. Subject must understand and voluntarily sign the informed consent form after receiving sufficient explanation for participation in this study
Exclusion criteria
Exclusion criteria: Subject who has complicated psychiatric illness or symptoms that interfere with daily life and is considered difficult to participate in the study Subject who has any medical condition that would prevent the subject from participating in the study based on investigator's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate at which any genetic abnormality is detected Percentage of each gene abnormality | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of somatic cell line mutations and mutation rate in exons Positive rate of biomarkers (things that are directly related to therapeutic drugs/treatment methods) Treatment options after oncogene panel testing Objective response rate (including correlation between biomarker and therapeutic response) Disease control rate Overall survival and progression free survival Number of germline mutations suspected and confirmed by Sanger sequencing | — |
Contacts
Public ContactTatsu Shimoyama
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Outcome results
None listed